CTLA4 and melanoma: Immunotherapy based on cytotoxic T lymphocyte-associated antigen 4 (CTLA4), programmed death-1 (PD-1), and programmed death ligand-1 (PD-L1) inhibitors has emerged as an effective treatment in melanoma and non–small-cell lung carcinoma [12, 13].